Cloud migration in regulated environments: Validation implications and best practices

By Stuart Ward, Head of Platform Strategy, IDBS

Cloud migration is reshaping the digital landscape for life‑sciences. For BioPharma organizations and other regulated industries, moving scientific processes, data and applications to the cloud is more than a lift and shift upgrade. It is a strategic shift with direct implications for profitability and innovation. Research shows that enterprises which move at least 60% of their systems into the cloud achieve around 11% higher annual profit growth.¹ Because cloud adoption accelerates product development and opens new revenue streams, it has become central to long‑term competitiveness.

Why regulated industries are moving to the cloud

Like other heavily regulated industries, BioPharma organizations historically relied on on‑premises systems to maintain tight control over sensitive data. However, the scale and complexity of modern research and development make it difficult for internal IT teams to keep pace with hardware refresh cycles, software updates and soaring data volumes. Cloud adoption is therefore becoming the default strategy: Leading IT researchers forecast that more than 85% of organizations will adopt a “cloud‑first” principle.²  And 70% of IT decision‑makers report that their organizations have accelerated migration to the cloud in the past 12 months.³ Major IT advisory firms also estimate that total cloud spending across all models could top US$825 billion.⁴

Migrating workloads to the cloud offers tangible benefits. Surveyed organizations credit cloud adoption with higher revenue growth. Around 71% of decision‑makers say revenues increased because of cloud services while small and medium‑sized businesses that make extensive use of cloud tools grow 26% faster and deliver 21% higher profits than those that do not.⁵ Moving to the cloud gives organizations on‑demand access to scalable computing, storage and advanced tools like machine learning, analytics and automation that accelerate research and development. At the same time, cloud environments simplify separation of duties and offer far more resilient backup and recovery capabilities than traditional on‑premise systems. For regulated industries, another factor is quality: product recalls in FDA- and CPSC-regulated sectors have increased 115% since 2018, underscoring the need for robust digital quality systems.⁶

Validation considerations

The promise of the cloud does not reduce regulatory obligations. Good Practice (GxP) guidelines, covering manufacturing (GMP), laboratory (GLP) and clinical (GCP) activities, require that systems producing, storing or analyzing regulated data be validated to ensure accuracy, reliability and data integrity. Compliance with U.S. FDA 21 CFR Part 11 and the EU’s Annex 11 remains mandatory whether systems run on‑premises or in the cloud. Cloud providers often offer technical controls such as audit trails, encryption and access management, and may supply documentation to support validation. Nonetheless, regulated companies remain responsible for demonstrating that software performs as intended and for maintaining evidence of planning, testing and execution.

Cloud security is a particular concern. A recent study reports that 55% of respondents find securing cloud environments more complex than securing on‑premises systems, while the previous report notes that secrets management and key management are top challenges.⁷ Misconfigurations, excessive privileges and weak encryption can compromise data integrity, so regulated organizations must treat validation and security as a continuous lifecycle rather than a one‑time event. This includes change control, periodic review and automated monitoring to ensure ongoing compliance.

Best practices for a compliant migration

Plan thoroughly. Begin with a comprehensive inventory of applications, data flows and regulatory requirements. Classify systems by criticality and risk, determine which workloads can be moved without modification and which need to be re‑architected, and engage quality, regulatory, scientific and IT stakeholders early. A robust roadmap not only aligns technical and business objectives but also supports risk‑based validation planning.

Embed validation into every stage. For each system, define its intended use, acceptance criteria and test plans. Perform installation, operational and performance qualifications in collaboration with your cloud vendor, and document each step. Use vendor‑supplied validation packages where appropriate, but verify that they align with your workflows and risk profile. Continuous validation also requires updating documentation and tests when systems change to ensure compliance.

Build strong security and governance. Implement least‑privilege access, encrypt data at rest and in transit, and employ monitoring tools to detect misconfigurations or unauthorized changes. Establish a governance body to define policies for data classification, retention and access. Many BioPharma organizations adopt hybrid or multi‑cloud strategies; in 2019, 84% of surveyed enterprises reported using multiple clouds.⁸ Gartner predicts that by 2027 more than 90% of organizations will combine multiple public clouds and on‑premises environments.⁹ Hybrid architectures allow sensitive workloads to remain in validated environments while less‑regulated applications benefit from the elasticity of public clouds, but they increase complexity. Standardized architectures and infrastructure‑as‑code templates help ensure consistency across environments.

Invest in training and change management. Cloud migration transforms workflows. Communicate why changes are necessary, provide training tailored to scientists, quality specialists and IT staff, and ensure that teams know how to use new tools securely and effectively. Post‑migration, monitor performance, cost and compliance metrics. Cloud adoption is iterative; continuous improvement ensures that benefits endure.

The bottom line

For regulated industries, moving to the cloud is both an opportunity and a responsibility. And nowhere is this imperative more urgent than BioPharma where even the slightest efficiency gains can accelerate the time for a drug to get to the patient. Evidence shows that substantial cloud adoption correlates with higher profitability, revenue growth and faster expansion for small and medium‑sized businesses. However, the regulatory stakes remain high, and security complexity is a real concern. By following a rigorous, risk‑based approach to planning, validation, security and training, regulated organizations can realize the benefits of cloud migration while maintaining compliance and safeguarding data integrity.

Make IDBS your trusted partner

Choosing the right partner is essential when moving sensitive scientific workloads to the cloud. IDBS has more than twenty years of regulatory, scientific and technical expertise and works with seventy five percent of the top twenty biopharmaceutical companies. Its GxP framework combines ISO 9001 and ISO 27001 certifications, continuous assurance through SOC 2 Type 2, and SOC 3 audits and products designed to comply with 21 CFR Part 11 and EudraLex Vol. 4 Annex 11 technical controls. IDBS delivers comprehensive services spanning GxP advisory, cloud implementation and validation support, ensuring that your migration is efficient and compliant.

By partnering with IDBS, you benefit from built‑in data integrity features that follow ALCOA++ principles, robust encryption and access controls, and a cross‑functional team dedicated to your success. Our experts work closely with your quality, IT and scientific teams to build a tailored migration roadmap, provide validation documentation and establish governance frameworks. Contact IDBS today to start your compliant cloud journey and unlock the agility and innovation potential of the cloud while protecting patient safety and meeting regulatory requirements head on.

While compliance is critical, it is only one part of the picture—cloud migration also plays a central role in driving business agility and long‑term performance. Read how BioPharma organizations are using the cloud to improve resilience, reduce costs and accelerate innovation.

Footnotes and sources

¹ Infosys. Cloud Radar 2021(2021). 

² TechRepublic. Gartner via TechRepublic/Aunalytics (2021).

³ Foundry. Cloud Computing Study (2025).

⁴ Deloitte Insights. Cloud gets lean:‘FinOps’makes every dollarwork harder (2024).

⁵ Deloitte study commissioned by Google. Small business, big technology: How the cloud enables rapid growth in SMBs (2014).

⁶ NCSC, Cloud security guidance (2026).

⁷ MasterControl.Quality first: Consumer product recalls have risen 115% since 2018 (2023).

⁸ SkyRadar. Enhancing cloud security: Insights from the 2024 Thales Cloud Security Study (2024).

⁹ Flexera. RightScale state of the cloud report (2019). 

¹⁰ Gartner. Gartner forecasts worldwide public cloud end-user spending to total $723 billion in 2025. (2024)

About the author

By Stuart Ward, Head of Platform Strategy, IDBS

Stuart is responsible for ensuring that IDBS’ software platform and products meet the needs of customers today and in the future. The Platform Strategy team provides the necessary business, technical and domain experience along with customer and market insights required to create software and solutions to enable BioPharma and other industries achieve faster scientific breakthroughs. In addition, he led the creation and launch of The E-WorkBook GxP Cloud, which was IDBS’ first SaaS product for use in regulated (21 CFR Part 11, GxP) environments. 

Before starting this role in January 2014, he was Product Manager for E-WorkBook for four years and worked in IDBS Global Professional Services for five years, responsible for deploying IDBS’ products both from a technical and project management perspective. 

Prior to working at IDBS, Stuart completed a post-doctoral fellowship at the NIH and then worked for Ionix Pharmaceuticals. Stuart obtained his PhD in Pharmacology from the MRC National Institute for Medical Research (University of London).